Juan Ignacio Damonte

Hospital Italiano de Buenos Aires

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Antonio Abbate

University of Virginia

Marco Giuseppe Del Buono

Università Cattolica del Sacro Cuore

Roshanak Markley

Virginia Commonwealth University

Juan Guido Chiabrando

Hospital Italiano de Buenos Aires

Jeremy Turlington

Virginia Commonwealth University

Benjamín Van Tassell

Virginia Commonwealth University

Salvatore Carbone

Virginia Commonwealth University

Georgia Thomas

University of Leicester

Cory R. Trankle

Virginia Commonwealth University

Azita H. Talasaz

Tehran University of Medical Sciences

Cooperative Institutions

Virginia Commonwealth University

Hospital Italiano de Buenos Aires

Icahn School of Medicine at Mount Sinai

Istituti di Ricovero e Cura a Carattere Scientifico

MedStar Washington Hospital Center

Virginia Commonwealth University Medical Center

University of Virginia

Harvard University

Cardiovascular Institute of the South

Mount Sinai Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Rheumatoid Arthritis, Statin Indication and Lipid Goals: Analysis According to Different Recommendations

Reumatología Clínica (2021)

Walter Masson Emiliano Rossi Rodolfo N. Alvarado Guillermo Cornejo-Peña Juan Ignacio Damonte

Nice

10.1016/j.reuma.2021.02.002

Cite

Citations (7)

277 Heart Failure Clinical Trial Enrollment at a Rural Satellite Hospital

Journal of Clinical and Translational Science (2022)

Antonio Abbate Yub Raj Sedhai Nimesh Patel Virginia Mihalick Azita H. Talasaz

OBJECTIVES/GOALS: Heart failure (HF) is a clinical condition that notably affects the lives of patients in rural areas. The partnering of a rural satellite hospital with an urban academic medical center may provide geographically underrepresented populations with HF an opportunity to access controlled clinical trials (CCTs). METHODS/STUDY POPULATION: We report our experience in screening, consenting and enrolling subjects at the VCU Health Community Memorial Hospital (VCU-CMH) in rural South Hill, Virginia, that is part of the larger VCU Health network, with the lead institution being VCU Health Medical College of Virginia Hospitals (VCU-MCV), Richmond, VA. Subjects were enrolled in a clinical trial sponsored by the National Institutes of Health (ClinicalTrials.gov: NCT03797001) and assigned to treatment with an anti-inflammatory drug for HF or placebo. We used the electronic health record and remote guidance and oversight from the VCU-MCV resources using a closed-loop communication network to work with local resources at the facility to perform screening, consenting and enrollment. RESULTS/ANTICIPATED RESULTS: One hundred subjects with recently decompensated HF were screened between January 2019 and August 2021, of these 61 are enrolled to date: 52 (85 %) at VCU-MCV and 9 (15%) at VCU-CMH. Of the subjects enrolled at VCU-CMH, 33% were female, 77% Black, with a mean age of 52ï‚±10 years. DISCUSSION/SIGNIFICANCE: The use of a combination of virtual/remote monitoring and guidance of local resources in this trial provides an opportunity for decentralization and access of CCTs for potential novel treatment of HF to underrepresented individuals from rural areas.

10.1017/cts.2022.150

Cite

Citations (0)

Effect of IL-1 Blockade With Anakinra on Heart Failure Outcomes in Patients With Anterior Versus Nonanterior ST Elevation Myocardial Infarction

Journal of Cardiovascular Pharmacology (2022)

Marco Giuseppe Del Buono Juan Ignacio Damonte Juan Guido Chiabrando Roshanak Markley Jeremy Turlington

Patients with ST elevation myocardial infarction (STEMI) are at risk of future heart failure (HF), particularly those with anterior STEMI. Interleukin-1 (IL-1) is a key mediator of the inflammatory response, and its blockade has emerged as a potential therapeutic strategy to prevent HF events. The aim of this analysis was to explore the effects of anakinra, an IL-1 receptor antagonist, on HF outcomes based on anterior versus nonanterior location STEMI and to explore whether this effect is mediated through the amelioration of left ventricular systolic function and cardiac remodeling. We pooled data from 3 early phase randomized clinical trials. The primary end point was a composite of all-cause death and new-onset HF at 1-year follow-up. The left anterior descending coronary artery as culprit vessel was used to identify anterior STEMI. We included 139 patients, 47 (34%) with anterior STEMI and 92 (66%) with nonanterior STEMI. Anakinra significantly reduced the combined end point of death or new-onset HF in patients with anterior STEMI [4 (13%) vs. 7 (42%), log-rank P value = 0.049] and in patients with nonanterior STEMI [3 (6%) vs. 9 (24%), log-rank P value = 0.014]. We found no significant differences comparing anakinra versus placebo in interval changes in left ventricular ejection fraction and volumes in anterior and nonanterior STEMI. In conclusion, anakinra is associated with a reduction of HF events in patients with STEMI, irrespective of anterior or nonanterior location, or of changes in left ventricular ejection fraction or cardiac remodeling.

Culprit

Ventricular remodeling

Clinical endpoint

10.1097/fjc.0000000000001240

Cite

Citations (6)

Rheumatoid Arthritis, Statin Indication and Lipid Goals: Analysis According to Different Recommendations

Reumatología Clínica (English Edition) (2022)

Walter Masson Emiliano Rossi Rodolfo N. Alvarado Guillermo Cornejo-Peña Juan Ignacio Damonte

Nice

10.1016/j.reumae.2021.02.010

Cite

Citations (0)

Skeletal muscle quality, measured via phase angle, and cardiorespiratory fitness in patients with obesity and heart failure with preserved ejection fraction

Nutrition (2023)

Hannah Salmons Syed Imran Ahmed Hayley Billingsley Roshanak Markley Juan Ignacio Damonte

Bioelectrical Impedance Analysis

Mass index

10.1016/j.nut.2023.112163

Cite

Citations (4)

Preservation of Cardiac Reserve and Cardiorespiratory Fitness in Patients With Acute De Novo Versus Acute on Chronic Heart Failure With Reduced Ejection Fraction

The American Journal of Cardiology (2021)

Marco Giuseppe Del Buono Virginia Mihalick Juan Ignacio Damonte Hayley Billingsley Alessandra Vecchiè

Interquartile range

Oxygen pulse

Pathophysiology

10.1016/j.amjcard.2021.07.036

Cite

Citations (3)

100.40 CTO-PCI in Patients With and Without Diabetes Mellitus: Insights From a University Hospital in Argentina

КАРДИОЛОГИЯ УЗБЕКИСТАНА (2025)

Juan Ignacio Damonte Juan Manuel Telayna NULL AUTHOR_ID Juan Manuel Telayna Ricardo Costantini

10.1016/j.jcin.2025.01.045

Cite

Citations (0)

Safety, tolerability and effects of a single subcutaneous administration of SP16–a SERPIN-like, small peptide agonist of the Low-Density Lipoprotein-like Receptor 1 –on the acute inflammatory response in patients with ST-segment elevation Myocardial Infarction (STEMI)

Journal of Cardiovascular Pharmacology (2022)

Benjamín Van Tassell George F. Wohlford Marco Giuseppe Del Buono Juan Ignacio Damonte Roshanak Markley

Background: Modulation of the inflammatory response is a promising therapeutic strategy in acute myocardial infarction. The novel approach is based on the anti-inflammatory and cytoprotective properties mediated by the engagement of the low-density lipoprotein‒related protein 1 (LRP1) receptor. SERPIN peptide 16 (SP16) is a synthetic, selective LRP1 agonist. We herein present the results of a study with a single subcutaneous administration of SP16 in 10 patients with STEMI, to appraise its safety and tolerability and explore the effects on the acute inflammatory response, infarct size, and cardiac function. Methods: Ten patients with ST-segment elevation myocardial infarction (STEMI) were enrolled within 12 hours of symptoms onset and 6 hours of percutaneous coronary intervention in a single-center, single-arm, open-label study of a single subcutaneous administration of SP16 (0.2 mg/kg). Serial clinical biomarkers and echocardiography data were collected up to 12 months. The data are presented separately for the treatment group and compared with historical controls from a placebo-treated arm in a recently completed clinical trial (N = 28) with similar enrollment criteria. Results: All ten patients with STEMI received subcutaneous administration of SP16, 381 [272–478] minutes after percutaneous coronary intervention, without any treatment-related adverse events. The area under the curve for C-reactive protein was 133 [46–528] mg·d/L in the SP16-treated group versus 286 [141–581] mg·d/L in the historical placebo-treated group ( P = 0.161). The area under the curve for creatine kinase–myocardial band was 1432 [675–3089] ng·d/mL in the SP16-treated group versus 2367 [830–4750] ng·d/mL in the historical placebo-treated patients ( P = 0.428). Left ventricular ejection fraction was 46% [39–54] at baseline and 51% [46–58] at 1 year follow-up in SP16-treated patients (interval change 5% [−0.3% to +9%] P = 0.05) and 44% [38%–56%] at baseline and 53% [43%–59%] at 1 year follow-up in historical placebo-treated patients (interval change 3% [−5% to 10%], P = 0.305). Conclusion: A single subcutaneous administration of SP16, a synthetic targeted LRP1 agonist, was safe and well-tolerated in patients with STEMI. A trend toward reduction in the inflammatory response and infarct size with SP16 was noted; however, the sample size for this study was not based on formal statistical criteria. More extensive studies are planned to determine the clinical efficacy of SP16 in STEMI. NCT: NCT04225533.

Tolerability

Creatine kinase

10.1097/fjc.0000000000001331

Cite

Citations (2)

Contents

The American Journal of Cardiology (2022)

Mohammed Essa Alireza Ghajar Augustin DeLago Matthew Hammond‐Haley Joseph Shalhoub

10.1016/s0002-9149(22)00373-3

Cite

Citations (0)

Effect of Interleukin-1 Blockade with Anakinra on Leukocyte Count in Patients with ST-Segment Elevation Acute Myocardial Infarction

Research Square (Research Square) (2021)

Marco Giuseppe Del Buono Juan Ignacio Damonte Cory R. Trankle Dinesh Kadariya Salvatore Carbone

Abstract Background. Leukocytosis is a common finding in patients with ST elevation myocardial infarction (STEMI) and portends a poor prognosis. Interleukin 1-b regulates leukopoiesis and pre-clinical studies suggest that anakinra (recombinant human interleukin-1 [IL-1] receptor antagonist) suppresses leukocytosis in myocardial infarction. However, the effect of IL-1 blockade with anakinra on leukocyte count in patients with STEMI is unknown. Methods . We reviewed the white blood cell (WBC) and differential count of 99 patients enrolled in a clinical trial of anakinra (n=64) versus placebo (n=35) for 14 days after STEMI. A complete blood cell count with differential count were obtained at admission, and after 72 hours, 14 days and 3 months. Results. After 72 hours from treatment, anakinra compared to placebo led to a statistically significant greater percent reduction in total WBC count (-35% [-48 to -24] vs -21% [-34 to -10], P =0.008), absolute neutrophil count (-48% [-60 to -22] vs -27% [-46 to -5], P =0.004) and to an increase in absolute eosinophil count (+50% [0 to +100] vs 0% [-50 to +62], P =0.022). These changes persisted while on treatment at 14 days and were no longer apparent at 3 months after treatment discontinuation. Conclusion . We found that in patients with STEMI IL-1 blockade with anakinra accelerates resolution of leukocytosis and neutrophilia. This modulation may represent one of the mechanisms by which IL-1 blockade improves clinical outcomes.

Leukocytosis

Neutrophilia

Discontinuation

White blood cell

Absolute neutrophil count

10.21203/rs.3.rs-959200/v1

Cite

Citations (1)